CA-LIQUID-INSTRUMENTS
23.3.2021 14:02:04 CET | Business Wire | Press release
Today, Liquid Instruments , an innovator in precision software-defined instrumentation, launched Moku:Go , a complete, portable platform designed to bring the engineering lab anywhere and usher in a new era of scientific and engineering education at universities around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210323005031/en/
Within higher education, current in-person lab instrumentation is stationary, expensive, hardware-limited and fixed at the time of purchase. Existing portable solutions lack the intuitive software interfaces that current and future generations of students have come to expect. They also do not offer all of the necessary instruments and features to enable students to learn effectively outside of the lab. The increasing demand for remote learning solutions and a more hands-on experience both in and out of the classroom has fueled the market need for student-owned, flexible platforms that can support the next generation of engineers and scientists.
The new software-enabled hardware platform, Moku:Go, is an engineering lab that can fit in a backpack. It was designed for maximum portability, flexibility and durability, to take not just electrical engineering students, but physics, bioengineering, chemical engineering and other majors through all four years of their education and even beyond. It starts with 8 proven, powerful instruments including an oscilloscope, PID controller, logic analyzer, arbitrary waveform generator, data logger, spectrum analyzer, and more. It also features full connectivity with a Wi-Fi hotspot and USB-C, robust hardware features and electrical protection to ensure that students can explore new projects without putting themselves or their equipment at risk. The unique integrated power supplies are user programmable with high voltage and high current options for any project.
“Our students were thrilled when we first added Moku:Lab to our classroom two years ago, and after seeing the new capabilities of Moku:Go, I’m even more excited. It is clear that it will help take students’ educational experience into the modern era,” said Colonel Brian J. Neff, Electrical & Computer Engineering Department Head at the United States Air Force Academy. “I look forward to seeing this become a standard part of our curriculum.”
Moku:Go’s software was designed to appeal to a generation that is accustomed to intuitive user interfaces and broad compatibility. Liquid Instruments is bringing the user experience out of the flip-phone era and has designed intuitive Windows and Mac interfaces that are inviting and powerful for students. It offers remote access capabilities and clearly diagrammed views of the signal processing chain, which makes it easy for students to learn difficult concepts whether they are in person or remote. The student-centric design ensures they are learning the core concepts, rather than just learning the equipment itself.
Not only does Moku:Go help increase student engagement, but incorporation into curriculum also reduces faculty and teaching assistant workloads. The platform supports Python, LabVIEW and MATLAB APIs and has published examples of MATLAB live scripts for remote instruction, live student assistance and plagiarism control.
Its robust feature set and sophisticated software can also unlock advanced capabilities for makers and even high school students looking to explore engineering. Whether they are learning the basics of resistors and op-amps or designing an advanced quadcopter with sensors and autonomous navigation, Moku:Go enables easier access to otherwise complex concepts and hands-on engineering projects anytime, anywhere at an affordable price.
Liquid Instruments is introducing Moku:Go for science and engineering students as part of its growing product portfolio of high-precision instrumentation solutions developed by its team of experimental physicists and engineers that know firsthand what is necessary to transform the way learning and research is performed at all levels. The existing product, Moku:Lab, has been utilized for years by top institutions worldwide, enabling breakthrough research in the areas of photonics, electronics, and materials science.
“Our first product, Moku:Lab, gave R&D scientists the power and flexibility they needed to do their job, all in a streamlined and cost-effective platform. Now with Moku:Go we will bring those same advantages to improve the overall quality of education and motivate students to study science and engineering,” said Professor Daniel Shaddock, CEO and co-founder of Liquid Instruments. “Students deserve lab equipment that is powerful and flexible, but also simple and fun to use. Improving access to critical educational tools will empower students from all walks of life to pursue a career in STEM.”
Moku:Go starts at $499 and can be customized to match school colors, with volume purchasing for educational institutions. For information on education discounts, accessories and full specifications, please visit the product page here .
For more information about Liquid Instruments and its full suite of products, please visit https://liquidinstruments.com .
About Liquid Instruments
Liquid Instruments is a leader in precision software-defined instrumentation and is revolutionizing the way that scientists, engineers, and students expand their knowledge and conduct research & development. Their product line of hardware and software solutions leverages the computational power of modern FPGAs to create highly customizable instrumentation for controlling experiments and acquiring and analyzing data. The team’s IP in software-defined hardware enables Moku products to be dynamically reconfigurable in the field, serving a wide range of ever-changing experimental and process control situations. Moku:Lab is used by hundreds of top R&D institutions worldwide, and brings 12+ high-value instruments together into a compact, intuitive device that has greatly streamlined experimental workflows. For more information, please visit https://liquidinstruments.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005031/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom